Table: Taisho Pharmaceutical HD - 6-MTH group results
Nov 10 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2023 Sep 30, 2022 Mar 31, 2024
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 163.10 144.52 319.00
(+12.9 pct) (+11.0 pct) (+5.8 pct)
Operating 16.36 12.21 20.50
(+34.0 pct) (+427.6 pct) (-10.9 pct)
Recurring 19.08 17.34 25.00
(+10.0 pct) (+310.7 pct) (-17.9 pct)
Net 7.45 10.88 10.50
(-31.5 pct) (+274.0 pct) (-44.7 pct)
EPS 90.89 yen 132.68 yen 128.09 yen
EPS Diluted 90.76 yen 132.52 yen
Ann Div 100.00 yen 100.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 50.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10